Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).

Autor: Wharton S; McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada., le Roux CW; St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland., Kosiborod MN; Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA., Platz E; Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA., Brueckmann M; Boehringer Ingelheim International GmbH, Ingelheim, Germany.; First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany., Jastreboff AM; Section of Endocrinology (Internal Medicine & Pediatrics) and Yale Obesity Research Center (Y-Weight), Yale School of Medicine, New Haven, Connecticut, USA., Ajaz Hussain S; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Pedersen SD; C-ENDO Diabetes and Endocrinology Clinic and University of Calgary, Calgary, Alberta, Canada., Borowska L; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Unseld A; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach/Riss, Germany., Kloer IM; Boehringer Ingelheim International GmbH, Ingelheim, Germany., Kaplan LM; Section of Obesity Medicine and Center for Digestive Health, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

Publikováno v: Obesity (Silver Spring, Md.) [Obesity (Silver Spring)] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.